Section
The TUXEDO-2 trial demonstrated that ultra-thin strut biodegradable polymer sirolimus-eluting stents are noninferior to durable polymer everolimus-eluting stents in diabetic patients with multivessel coronary artery disease at 1-year follow
This study explores how various social adversity domains affect mortality and rehospitalization risks in HIV-positive patients with heart failure, underscoring the importance of holistic social assessments for improving outcomes.
Emerging evidence indicates that radiation dose to the left anterior descending coronary artery better predicts cardiac events than whole-heart dose in breast radiotherapy, emphasizing the importance of LAD-based planning to reduce long-ter
This study demonstrates that continuous glucose monitoring-derived time in range (TIR) is independently associated with progression of arterial stiffness in type 2 diabetes, highlighting TIR as a valuable metric beyond HbA1c for cardiovascu
This review synthesizes evidence from a pioneering nonrandomized trial demonstrating that intravenous AAVrh.10hFXN gene therapy is safe and may improve cardiac outcomes in Friedreich ataxia cardiomyopathy, highlighting translational advance
Spatial proteomics reveals immune and metabolic heterogeneity in cardiac sarcoidosis, identifying new diagnostic protein signatures beyond granulomatous lesions.
This large-scale study links specific PM2.5 components, especially chloride, black carbon, and sulfate, to increased long-term cardiovascular disease risk, emphasizing targeted pollution control for better heart health.
This sham-controlled trial demonstrates that pulsed field ablation significantly reduces atrial fibrillation recurrence, burden, and improves quality of life and psychological distress compared to sham treatment.
The left atrial to ventricular volume ratio (LA:LV ratio) emerges as a superior marker over left atrial volume index (LAVi) for atrial cardiopathy, showing stronger association with ischemic stroke risk, cognitive decline, and atrial fibril
The MAPLE-HCM trial demonstrates aficamten monotherapy significantly outperforms metoprolol in improving exercise capacity, hemodynamics, and patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM), supporting aficamten
The FOREST-HCM long-term study confirms aficamten’s efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.
This study demonstrates that septal myectomy combined with cutting of secondary mitral valve chordae delivers excellent long-term survival and symptom relief in obstructive hypertrophic cardiomyopathy patients unresponsive to medical therap
Elevated lipoprotein(a) increases coronary artery disease risk, but this study reveals that inflammation—particularly IL-6 levels—modulates this risk, highlighting the importance of inflammatory biomarkers in cardiovascular risk assessment
The PREVUE-VALVE study reveals a significant prevalence of moderate or greater valvular heart disease among U.S. adults aged 65-85, highlighting substantial public health implications and the value of decentralized echocardiographic screeni
Genetic variants enriched in individuals of African ancestry confer increased risk of cardiomyopathy and arrhythmias, with cardiovascular risk factors amplifying this risk. Large biobank studies enable reclassification of key variants and h
This study assesses the accuracy of emergency physician-interpreted point-of-care ultrasound compared to cardiologist-interpreted consultative echocardiography for detecting right ventricular dysfunction in emergency patients with pulmonary
A multicomponent stewardship intervention significantly reduced inappropriate antiplatelet prescription among patients on DOACs, decreasing bleeding risk, particularly in stable coronary artery disease.
Latent class analysis of 889 adult PAH-CHD patients identified unique phenogroups with distinct survival outcomes and treatment responses, offering refined risk stratification and guiding personalized therapy.
Elevated parathyroid hormone at the high-normal range independently predicts greater cardiovascular and all-cause mortality, with marked sex and age disparities in a large middle-aged Brazilian cohort.
The OPTN’s new status escalation policy for stable adult heart transplant candidates with durable LVADs may benefit only a small fraction of patients, as most experience complications or transplant within six years.
